N-(2-aminoethyl)piperidine-4-carboxamide | 1221567-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(2-aminoethyl)piperidine-4-carboxamide
• CAS: 1221567-06-1
• 化学式: C₈H₁₇N₃O
• 分子量: 171.242
• InChiKey: YMDISBGROMNAQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018183411A1

  公开（公告）日：2018-10-04

  Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  公式（I）的化合物被披露为DCNl的抑制剂，以及含有这些化合物的组合物。还披露了在治疗疾病和病况中使用DCNl抑制剂的方法，其中DCNl的抑制提供益处，如氧化应激相关的疾病和病况、神经退行性疾病和病况、代谢紊乱以及肌肉神经退化。
• [EN] PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS À BASE DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT POUR LE TRAITEMENT DU CANCER
  申请人：CANCER REC TECH LTD

  公开号：WO2010041054A1

  公开（公告）日：2010-04-15

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and / or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物，包括这些化合物的药物组合物，以及它们作为治疗和/或预防癌症的潜在用途。
• [EN] NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZOPYRAZINE EN TANT QU'ANTIBACTÉRIENS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020126953A1

  公开（公告）日：2020-06-25

  The invention provides novel imidazopyrazine derivatives having general formula (I), wherein R1 to R11 are as described herein, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

  这项发明提供了具有通式（I）的新型咪唑吡嗪衍生物，其中R1至R11如本文所述，并其药学上可接受的盐。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染及相关疾病的方法。
• PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：McDonald Edward

  公开号：US20110190297A1

  公开（公告）日：2011-08-04

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and/or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物，包括这些化合物的药物组合物以及它们作为治疗和/或预防癌症的治疗剂的潜在用途。
• SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：The Regents of The University of Michigan

  公开号：EP3601245A1

  公开（公告）日：2020-02-05